Immunogenicity and protective efficacy of Gag/Pol/Env vaccines derived from temporal isolates of SIVmne against cognate virus challenge

Journal of Medical Primatology

Volumn 36, Issue 4-5, 2007, Pages 254-265

  Polacino, Patricia ^a   Cleveland, Brad ^a   Zhu, Yongde ^a   Kimata, Jason T ^b   Overbaugh, Julie ^c   Anderson, David ^a   Hu, Shiu Lok ^a,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d NONE   (United States)

Author keywords

AIDS; Chimeric virus; Pig tailed macaques; Prime boost; Vaccinia

Indexed keywords

GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; POL PROTEIN; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EXPERIMENTAL MODEL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; INOCULATION; LENTIVIRINAE; MACACA; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME; VIRUS IMMUNITY; VIRUS ISOLATION; VIRUS LOAD; VIRUS TRANSMISSION; VIRUS VIRULENCE;

ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; GENE PRODUCTS, POL; IMMUNOPHENOTYPING; INTERFERON TYPE II; MACACA NEMESTRINA; RETROVIRIDAE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, SYNTHETIC; VIRAL LOAD;

ANIMALIA; LENTIVIRUS; MACACA NEMESTRINA;

EID: 34547100081     PISSN: 00472565     EISSN: 16000684     Source Type: Journal    
DOI: 10.1111/j.1600-0684.2007.00243.x     Document Type: Conference Paper

References (57)

1. Benveniste RE, Arthur LO, Tsai CC, Sowder R, Copeland TD, Henderson LE, Oroszlan S: Isolation of a lentivirus from a macaque with lymphoma: comparison with HTLV-III/LAV and other lentiviruses. J Virol 1986; 60: 483-90.
2. Benveniste RE, Hill RW, Eron LJ, Csaikl UM, Knott WB, Henderson LE, Sowder RC, Nagashima K, Gonda MA: Characterization of clones of HIV-1 infected HuT 78 cells defective in gag gene processing and of SIV clones producing large amounts of envelope glycoprotein. J Med Primatol 1990; 19: 351-66.
3. Berlioz-Torrent C, Shacklett BL, Erdtmann L, Delamarre L, Bouchaert I, Sonigo P, Dokhelar MC, Benarous R: Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins. J Virol 1999; 73: 1350-61.
4. Bhattacharya J, Peters PJ, Clapham PR: Human immunodeficiency virus type 1 envelope glycoproteins that lack cytoplasmic domain cysteines: Impact on association with membrane lipid rafts and incorporation onto budding virus particles. J Virol 2004; 78: 5500-6.
5. Bowers K, Pelchen-Matthews A, Honing S, Vance PJ, Creary L, Haggarty BS, Romano J, Ballensiefen W, Hoxie JA, Marsh M: The Simian immunodeficiency virus envelope glycoprotein contains multiple signals that regulate its cell surface expression and endocytosis. Traffic 2000; 1: 661-74.
6. Byland R, Vance PJ, Hoxie JA, Marsh M: A conserved Dileucine Motif mediates clathrin and AP-2-dependent endocytosis of the HIV-1 envelope protein. Mol Biol Cell 2007; 18: 414-25.
7. Chakrabarti S, Sisler JR, Moss B: Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 1997; 23: 1094-7.
8. Cooney EL, McElrath MJ, Corey L, Hu SL, Collier AC, Arditti D, Hoffman M, Coombs RW, Smith GE, Greenberg PD: Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci USA 1993; 90: 1882-6.
9. De Wolf F, Hogervorst E, Goudsmit J, Fenyo EM, Rubsamen-Waigmann H, Holmes H, Galvao-Castro B, Karita E, Wasi C, Sempala SD et.al.: Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: Phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses 1994; 10: 1387-400.
10. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, Heil ML, Kasolo F, Musonda R, Hahn BH, Shaw GM, Korber BT, Allen S, Hunter E: Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004; 303: 2019-22.
11. Fenyo EM: HIV-1 biological phenotype varies with severity of infection across HIV-1 genetic subtypes. Antibiot Chemother 1996; 48: 49-55.
12. Freed EO, Martin MA: Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix. J Virol 1995; 69: 1984-9.
13. Hu SL, Abrams K, Barber GN, Moran P, Zarling JM, Langlois AJ, Kuller L, Morton WR, Benveniste RE: Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 1992; 255: 456-9.
14. Hu SL, Kosowski SG, Dalrymple JM: Expression of AIDS virus envelope gene in recombinant vaccinia viruses. Nature 1986; 320: 537-40.
15. Hu SL, Travis BM, Garrigues J, Zarling JM, Sridhar P, Dykers T, Eichberg JW, Alpers C: Processing, assembly, immunogenicity of human immunodeficiency virus core antigens expressed by recombinant vaccinia virus. Virology 1990; 179: 321-9.
16. Hu SL, Zarling JM, Chinn J, Travis BM, Moran PA, Sias J, Kuller L, Morton WR, Heidecker G, Benveniste RE: Protection of macaques against simian AIDS by immunization with a recombinant vaccinia virus expressing the envelope glycoproteins of simian type D retrovirus. Proc Natl Acad Sci USA 1989; 86: 7213-7.
17. Johnston PB, Dubay JW, Hunter E: Truncations of the simian immunodeficiency virus transmembrane protein confer expanded virus host range by removing a block to virus entry into cells. J Virol 1993; 67: 3077-86.
18. Kimata JT, Kuller L, Anderson DB, Dailey P, Overbaugh J: Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat Med 1999; 5: 535-41.
19. Kimata JT, Overbaugh J: The cytopathicity of a simian immunodeficiency virus Mne variant is determined by mutations in Gag and Env. J Virol 1997; 71: 7629-39.
20. Klaniecki JE, Dykers T, Travis BM, Schmitt R, Wain M, Watson A, Sridhar P, McClure J, Morein B, Ulrich JT, Hu SL, Lewis JB: Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus. AIDS Res Hum Retroviruses 1991; 7: 791-8.
21. Kostrikis LG, Cao Y, Ngai H, Moore JP, Ho DD: Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, I: Lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol 1996; 70: 445-58.
22. LaBranche CC, Sauter MM, Haggarty BS, Vance PJ, Romano J, Hart TK, Bugelski PJ, Hoxie JA: Biological, molecular, structural analysis of a cytopathic variant from a molecularly cloned simian immunodeficiency virus. J Virol 1994; 68: 5509-22.
23. Leitner T, Foley B, Hahn B, Marx P, McCutchan F, Mellors J, Wolinsky S, Korber B: HIV Sequence Compendium 2005. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory.
24. Lin X, Derdeyn CA, Blumenthal R, West J, Hunter E: Progressive truncations C terminal to the membrane-spanning domain of Simian immunodeficiency virus Env reduce fusogenicity and increase concentration dependence of Env for fusion. J Virol 2003; 77: 7067-77.
25. Manrique JM, Celma CCP, Affranchino JL, Hunter E, Gonzalez SA: Small variations in the length of the cytoplasmic domain of the simian immunodeficiency virus transmembrane protein drastically affect envelope incorporation and virus entry. AIDS Res Hum Retroviruses 2001; 17: 1615-24.
26. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo CR Jr: Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946-54.
27. Miller MA, Cloyd MW, Liebmann J, Rinaldo CR, Islam KR, Wang SZS, Mietzner TA, Montelaro RC: Alterations in cell membrane permeability by the lentivirus lytic peptide (LLP-1) of HIV-1 transmembrane protein. Virology 1993; 196: 89-100.
28. Moore JP, Cao Y, Leu J, Qin L, Korber B, Ho DD: Inter- and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 1996; 70: 427-44.
29. Overbaugh J, Rudensey LM, Papenhausen MD, Benveniste RE, Morton WR: Variation in simian immunodeficiency virus env is confined to V1 and V4 during progression to simian AIDS. J Virol 1991; 65: 7025-31.
30. Overholser ED, Babas T, Zink MC, Barber SA, Clements JE: CD4-independent entry and replication of simian immunodeficiency virus in primary rhesus macaque astrocytes are regulated by the transmembrane protein. J Virol 2005; 79: 4944-51.
31. Polacino P, Stallard V, Klaniecki JE, Montefiori DC, Langlois AJ, Richardson BA, Overbaugh J, Morton WR, Benveniste RE, Hu SL: Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. J Virol 1999; 73: 618-30.
32. Polacino PS, Stallard V, Klaniecki JE, Pennathur S, Montefiori DC, Langlois AJ, Richardson BA, Morton WR, Benveniste RE, Hu SL: Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques. J Virol 1999; 73: 8201-15.
33. Polacino P, Stallard V, Montefiori DC, Brown CR, Richardson BA, Morton WR, Benveniste RE, Hu SL: Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines. J Virol 1999; 73: 3134-46.
34. Richman DD, Wrin T, Little SJ, Petropoulos CJ: Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003; 100: 4144-9.
35. Rossio JL, Esser MT, Suryanarayana K, Schneider DK, Bess JW Jr, Vasquez GM, Wiltrout TA, Chertova E, Grimes MK, Sattentau Q, Arthur LO, Henderson LE, Lifson JD: Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol 1998; 72: 7992-8001.
36. Rousso I, Mixon MB, Chen BK, Kim PS: Palmitoylation of the HIV-1 envelope glycoprotein is critical for viral infectivity. Proc Natl Acad Sci USA 2000; 97: 13523-5.
37. Rowell JF, Stanhope PE, Siliciano RF: Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC. J Immunol 1995; 155: 473-88.
38. Rudensey LM, Kimata JT, Benveniste RE, Overbaugh J: Progression to AIDS in macaques is associated with changes in the replication, tropism, cytopathic properties of the simian immunodeficiency virus variant population. Virology 1995; 207: 528-42.
39. Rudensey LM, Kimata JT, Long EM, Chackerian B, Overbaugh J: Changes in the extracellular envelope glycoprotein of variants that evolve during the course of simian immunodeficiency virus SIVMne infection affect neutralizing antibody recognition, syncytium formation, and macrophage tropism but not replication, cytopathicity, or CCR-5 coreceptor recognition. J Virol 1998; 72: 209-17.
40. Sagar M, Wu X, Lee S, Overbaugh J: Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 2006; 80: 9586-98.
41. Saha K, Yan H, Nelson JAE, Zerhouni-Layachi B: Infection of human and non-human cells by a highly fusogenic primary CD4-independent HIV-1 isolate with a truncated envelope cytoplasmic tail. Virology 2005; 337: 30-44.
42. Sauter MM, Pelchen-Matthews A, Bron R, Marsh M, LaBranche CC, Vance PJ, Romano J, Haggarty BS, Hart TK, Lee WM, Hoxie JA: An internalization signal in the simian immunodeficiency virus transmembrane protein cytoplasmic domain modulates expression of envelope glycoproteins on the cell surface. J Cell Biol 1996; 132: 795-811.
43. Spies CP, Compans RW: Effects of cytoplasmic domain length on cell surface expression and syncytium-forming capacity of the simian immunodeficiency virus envelope glycoprotein. Virology 1994; 203: 8-19.
44. Srinivas SK, Srinivas RV, Anantharamaiah GM, Compans RW, Segrest JP: Cytosolic domain of the human immunodeficiency virus envelope glycoproteins binds to calmodulin and inhibits calmodulin-regulated proteins. J Biol Chem 1993; 268: 22895-9.
45. Suryanarayana K, Wiltrout TA, Vasquez GM, Hirsch VM, Lifson JD: Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction. AIDS Res Hum Retroviruses 1998; 14: 183-9.
46. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM: Antibody neutralization and escape by HIV-1. Nature 2003; 422: 307-12.
47. West JT, Johnston PB, Dubay SR, Hunter E: Mutations within the putative membrane-spanning domain of the simian immunodeficiency virus transmembrane glycoprotein define the minimal requirements for fusion, incorporation, and infectivity. J Virol 2001; 75: 9601-12.
48. Wyma DJ, Kotov A, Aiken C: Evidence for a stable interaction of gp41 with Pr55Gag in immature human immunodeficiency virus type 1 particles. J Virol 2000; 74: 9381-7.
49. Wyss S, Berlioz-Torrent C, Boge M, Blot G, Honing S, Benarous R, Thali M: The highly conserved c-terminal dileucine motif in the cytosolic domain of the human immunodeficiency virus type 1 envelope glycoprotein is critical for its association with the ap-1 clathrin adapter. J Virol 2001; 75: 2982-92.
50. Wyss S, Dimitrov AS, Baribaud F, Edwards TG, Blumenthal R, Hoxie JA: Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail. J Virol 2005; 79: 12231-41.
51. Yang C, Spies CP, Compans RW: The human and simian immunodeficiency virus envelope glycoprotein transmembrane subunits are palmitoylated. Proc Natl Acad Sci U S A 1995; 92: 9871-5.
52. Yuste E, Johnson W, Pavlakis GN, Desrosiers RC: Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus. J Virol 2005; 79: 12455-63.
53. Yuste E, Reeves JD, Doms RW, Desrosiers RC: Modulation of Env content in virions of simian immunodeficiency virus: Correlation with cell surface expression and virion infectivity. J Virol 2004; 78: 6775-85.
54. Zarling JM, Morton WR, Moran PA, McClure J, Kosowski SG, Hu SL: T-cell responses to human AIDS virus in macaques immunized with recombinant vaccinia viruses. Nature 1986; 323: 344-6.
55. Zhang H, Hoffmann F, He J, He X, Kankasa C, West J, Mitchell C, Ruprecht R, Orti G, Wood C: Characterization of HIV-1 subtype C envelope glycoproteins from perinatally infected children with different courses of disease. Retrovirology 2006; 3: 73.
56. Zhu P, Liu J, Bess J, Chertova E, Lifson JD, GriséH, Ofek GA, Taylor KA, Roux KH: Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006; 441: 847-52.
57. Zolla-Pazner S, Gomy MK, Nyambi PN: The implications of antigenic diversity for vaccine development. Immunol Lett 1999; 66: 159-64.